Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,608.50
Bid: 1,607.00
Ask: 1,608.50
Change: -1.50 (-0.09%)
Spread: 1.50 (0.093%)
Open: 1,611.50
High: 1,614.00
Low: 1,608.00
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks holding higher for now

Wed, 06th Feb 2013 12:00

By the midday mark the Footsie was continuing to trade slightly higher, tracking overnight gains on Wall Street and in Tokyo.The latter came in response to news that Bank of Japan Governor, Masaaki Shirakawa, will step down on March 19th, almost three weeks ahead of schedule, which some observers interpreted as favouring the new Prime Minister's calls for a more aggressive monetary policy. All of the above comes ahead of tomorrow's testimony by Mark Carney before the Treasury Select Committee and policy meetings at the Bank of England and the European Central Bank. Not to be lost sight of, investors are also watching what appear to be signs of division between France and southern Europe, on the one hand, and Germany and the UK on the other, ahead of tomorrow's European Council. European leaders are expected to try to find an agreement on the European Budget for 2014-2020. Commenting on those differences, this is what Barclays Research had to say: "This negative signal, together with recent fears of political instability in Spain and in Italy, suggest that Europe is not yet out of the crisis, even though the ECB's threat of triggering the OMT should prevent a massive sell-off like in the first half of 2012." Further muddying the waters, overnight ratings agency Fitch cut its outlook on the Netherlands' sovereign debt rating. FTSE 100: Keep them coming says HargreavesIn UK company news, financial service company Hargreaves Lansdown on Wednesday posted record revenues and profits for the last half of 2012 driven by a boost in client numbers. Those prompted an upgrade out of Cannacord to buy. FTSE 100-listed metal mining company Eurasian Natural Resources is higher following the release of its fourth quarter production update. The fourth quarter Kazhak iron ore operations saw a strong rebound. Coal was another area of strength according to analysts, while the fall in copper output was due to power issues in the DRC. Pharmaceutical giant GlaxoSmithKline has announced a core fourth quarter earnings per share number of 32.6p, versus the 30.9p expected by the analyst consensus.Shares of Schroders are rising strongly following an upgrade out of analysts at Morgan Stanley, to overweight.Unilever, on the other hand, is leading losers this morning after going ex-dividend. ARM Holdings is off a tad following yesterday's surge and after at least three brokers (Investec, UBS and JP Morgan) opted to retain their 'neutral' rating on the stock. Analysts at the last of these three brokers said that "valuation remains elevated in our view, but as long as the company does not miss, we believe the stock will go up on upgrades." RBS has announced that it is in late stage settlement discussions with regulators and that it will update the market 'shortly', although it sees significant penalties and sanctions. FTSE 250: WS Atkins trading 'in line'Analysts at UBS have added shares of Man to their "most preferred" list, saying that "We are adding Man Group to our most preferred list. Following December's change of leadership, we believe that management could announce material strategic changes on February 28th (fiscal year results). A review of the company's distribution capabilities (downsizing and/or adding product at minimal cost) looks likely. Long term, we believe a sale of the company remains a possibility." Engineering and product management consultancy Atkins on Wednesday said it was trading in line with expectations despite challenging market conditions. The FTSE 250 company has faced difficult trading conditions over the past three months, particularly in North America, according to a business update. International home emergency business HomeServe has reported that it expects its New Markets segment to report a fiscal year 2013 operating loss of approximately £5.5m, representing a 61.8% rise in loss for this particular business segment compared to the fiscal year 2012, when the New Markets business reported a £3.4m loss.FTSE 100 - RisersHargreaves Lansdown (HL.) 799.00p +8.78%Eurasian Natural Resources Corp. (ENRC) 367.00p +6.62%Schroders (SDR) 2,005.00p +3.19%International Consolidated Airlines Group SA (CDI) (IAG) 220.80p +2.65%Burberry Group (BRBY) 1,425.00p +2.52%Pearson (PSON) 1,224.00p +2.26%Kazakhmys (KAZ) 740.00p +2.00%Antofagasta (ANTO) 1,135.00p +1.98%Weir Group (WEIR) 2,059.00p +1.88%Tullow Oil (TLW) 1,205.00p +1.77%FTSE 100 - FallersUnilever (ULVR) 2,554.00p -1.66%BP (BP.) 463.75p -1.06%Aviva (AV.) 353.60p -1.06%Rexam (REX) 464.20p -0.81%InterContinental Hotels Group (IHG) 1,902.00p -0.47%Barclays (BARC) 294.00p -0.42%Royal Dutch Shell 'A' (RDSA) 2,200.00p -0.34%Royal Dutch Shell 'B' (RDSB) 2,249.50p -0.29%Vodafone Group (VOD) 170.75p -0.29%SSE (SSE) 1,411.00p -0.28%FTSE 250 - RisersTullett Prebon (TLPR) 270.40p +7.47%ICAP (IAP) 359.70p +6.17%Enterprise Inns (ETI) 100.50p +6.07%Man Group (EMG) 95.80p +5.56%IG Group Holdings (IGG) 487.60p +4.52%New World Resources A Shares (NWR) 272.40p +4.17%TalkTalk Telecom Group (TALK) 250.00p +3.31%3i Group (III) 274.00p +3.16%Rathbone Brothers (RAT) 1,444.00p +3.07%Senior (SNR) 206.40p +2.99%FTSE 250 - FallersVictrex (VCT) 1,506.00p -2.02%Aberforth Smaller Companies Trust (ASL) 745.00p -1.65%Centamin (DI) (CEY) 61.60p -1.52%Invensys (ISYS) 344.70p -1.51%Genus (GNS) 1,444.00p -1.43%UBM (UBM) 731.00p -1.28%Inmarsat (ISAT) 653.00p -1.21%Spirax-Sarco Engineering (SPX) 2,350.00p -1.05%Debenhams (DEB) 97.60p -0.91%Diploma (DPLM) 575.00p -0.86%FTSE TechMARK - RisersXaar (XAR) 288.80p +3.88%Torotrak (TRK) 24.25p +3.19%Innovation Group (TIG) 25.00p +1.01%Kofax (KFX) 328.00p +0.92%Optos (OPTS) 199.00p +0.51%RM (RM.) 72.26p +0.36%Consort Medical (CSRT) 692.50p +0.07%Triad Group (TRD) 7.00p 0.00%Parity Group (PTY) 23.88p 0.00%Hiwave Technologies (HIW) 0.72p 0.00%FTSE TechMARK - FallersWolfson Microelectronics (WLF) 187.00p -5.56%Promethean World (PRW) 22.55p -4.04%Phytopharm (PYM) 8.50p -2.86%Oxford Biomedica (OXB) 2.20p -2.22%Gresham Computing (GHT) 71.25p -1.72%Ricardo (RCDO) 401.50p -1.35%E2V Technologies (E2V) 105.75p -1.17%Ark Therapeutics Group (AKT) 1.00p -0.50%Sepura (SEPU) 97.00p -0.39%Antisoma (ASM) 1.86p -0.27%AB
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.